Drug Profile
N-Acetylcarnosine
Alternative Names: Can-C; NAC - Innovative Vision Products; Nu-EyesLatest Information Update: 18 Jul 2007
Price :
$50
*
At a glance
- Originator Innovative Vision Products
- Class Dipeptides; Eye disorder therapies; Neuropeptides
- Mechanism of Action Antioxidants; Glycosylation inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Marketed Cataracts
- Phase Unknown Eye disorders
Most Recent Events
- 18 Jul 2006 Launched for Cataracts in World (Ophthalmic)
- 18 Jul 2004 Investigation in Eye disorders in USA (Ophthalmic)
- 16 Apr 2002 Clinical trials in Cataracts in Russia (Topical)